Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24796402 | 1.00 | CYP1A2 (0.38) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24796003 | 0.90 | CYP1A2 (0.37) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24796137 | 0.88 | CYP1A2 (0.39) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24796027 | 0.87 | CYP1A2 (0.36) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24796674 | 0.87 | CYP1A2 (0.36) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24796300 | 0.86 | CYP1A2 (0.40) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL21389368 | 0.86 | CYP1A2 (0.36) | CYP1A2CYP3A4ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL24795884 | 0.84 | USP2 (0.37) | CYP1A2ALDH1A1KMT2AL3MBTL1KDM4E | |
| SCHEMBL21389449 | 0.84 | ALDH1A1 (0.34) | ALDH1A1KMT2ASMN1; SMN2L3MBTL1NPC1 | |
| SCHEMBL21389230 | 0.84 | USP2 (0.37) | CYP1A2ALDH1A1KMT2AL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | CYP1A2 4309/4885CYP3A4 4044/4885ALDH1A1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.